Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year High at $40.00

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $40.00 and last traded at $40.00, with a volume of 413 shares traded. The stock had previously closed at $39.44.

Analyst Ratings Changes

MIRM has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, July 8th. Baird R W upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Monday, June 17th. JPMorgan Chase & Co. increased their target price on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Citigroup increased their target price on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th. Finally, Morgan Stanley increased their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.64.

Mirum Pharmaceuticals Price Performance

The firm’s 50 day moving average is $28.76 and its 200 day moving average is $27.53. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.47 and a current ratio of 3.68.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. The firm had revenue of $69.22 million for the quarter, compared to analysts’ expectations of $69.71 million. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.66 earnings per share for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the transaction, the insider now owns 27,406 shares of the company’s stock, valued at approximately $931,804. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the completion of the sale, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The disclosure for this sale can be found here. Insiders sold a total of 35,934 shares of company stock valued at $1,180,156 in the last quarter. Corporate insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. AJOVista LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $40,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $41,000. StepStone Group LP bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $135,000. China Universal Asset Management Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 447.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock valued at $159,000 after buying an additional 4,408 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $194,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.